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Working Group and for facilitating collection and distribution of the information resulting from this project.
The ARMWG is an all-volunteer effort. There is no funding to support this initiative. Although members of the ARMWG have held different points of view on issues, working group discussions have lead to (near) consensus decisions. This may seem an ideal situation but the highly cooperative and collaborative spirit behind the ARMWG effort was driven by the death of a patient in 1999, public perceptions of adenovirus gene therapy following that event, and a reassessment of work in the adenovirus vector field (2) .
The ARMWG first established a list of all of the activities that were involved in manufacture, characterization, and storage and distribution of a reference material. The ARMWG then established the criteria upon which selection of responsible groups would be made. This was done in conjunction with establishment of a rough timeline for the activities grouped by phase, manufacturing or characterization. Groups were asked to submit proposals for performing each activity based on the established criteria. Proposals were circulated to all members of the ARMWG in advance of Working Group meetings. FDA evaluated each proposal and CBER's representatives made recommendations to the ARMWG for their consideration. Decisions on all proposals and the selection of the group(s) to be assigned were made by a vote of the Working Group. FDA representatives abstained from all votes.
All information regarding the development of the Adenovirus Reference Material is freely available. All ARMWG meeting minutes, including summaries of discussions related to The ARMWG has obtained donations of materials and services to produce more than 5000 x 0.5-mL vials of a reference material consisting of Adenovirus 5 WT. The ARMWG selected the formulation of 20 mM TRIS, pH 8.0, 25 mM Sodium Chloride, 2.5% (w/v) Glycerol for the reference material. The ARMWG also obtained manufacturing materials for generation of additional batches of the reference, including a 293 cell production bank, an Adenovirus 5 WT production virus bank, a 293 cell testing phase bank, and repository services for storing and distributing the reference material and its manufacturing materials. The institutions involved in the manufacturing phase are shown in Table 1 .
The Adenovirus Reference Material is being characterized by a consortium of more than twentyfour laboratories around the world, including laboratories in the United States, Canada, the United Kingdom, and France. Characterization phase activities include a five-year long-term stability study, a short term field use and shipping configuration stability study, determination of particle concentration, determination of the infectious titer, sequence determination for the full length virus, and various analyses for impurities. Characterization is on track for public release of the Reference Material in spring 2002. Participating laboratories and assigned characterization activities are detailed in Table 2 .
Particle concentration is being determined by fifteen laboratories using a procedure developed by the ARMWG based on OD260nm absorbance in the presence of SDS. The goal is to obtain 60 data points based on 30 independently made sample dilutions. A small consortium of five laboratories is also determining particle concentration using a variety of orthogonal methods, including a Reverse Phase-HPLC assay (3), Anion Exchange HPLC assay (4), quantitative realtime PCR, a PicoGreen assay (5), and electron microscopy. Several other institutions are performing their institution-specific protocols for quantitative real-time PCR and Anion Exchange HPLC. They will provide the data and method details to the Working Group. The Working Group expects to be able to comment on the utility of the different orthogonal methods in comparison with the traditional absorbance method.
Infectious titer is being determined in seventeen laboratories using a procedure developed by the ARMWG. The method is based on a read-out of cytopathic effect (CPE) after ten days on 293 cells in a 96-well plate format. The 293 cells for the infectious titer assays were supplied by the ARMWG so that every group uses the same system. The Working Group selected a CPE-based assay because [1] the group desired a method that could be performed by most laboratories, [2] the group desired a method that was not dependent on specific equipment (such as flowcytometry based methods), and [3] the group desired a method that was easy to learn and perform by laboratory technical staff (as compared to plaque-formation assays which require more training to perform). Each laboratory is performing the assay on two independently created square root of two-fold dilution series. This will result in a large number of data points from each laboratory. The Working Group also decided that the assay should incorporate a correction
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for the slow diffusion of the adenovirus particle in solutions into the titer calculation from the raw data. The NAS titer calculation method was selected (6).
Several individual laboratories are performing their in-house infectious titer assays and will provide the data and method details to the Working Group as part of the characterization assessment. The methods include a plaque forming unit (pfu) assay, a flow cytometry-based infectious titer assay, and a different format CPE-based infectious titer assay. Relatively few groups were interested in assessing the reference material via in-house methods. The Working Group believes that most laboratories would prefer to assess the performance of their in-house infectious titer method without disclosing the data to the public. All information and data created under the Working Group's charter is available to the public. No information is allowed to remain proprietary as a condition of participation in the development of the reference material.
After reviewing all available data and receiving the recommendations from the FDA representatives, the Working Group will determine and officially assign both the particle concentration and the infectious unit concentration, i.e., infectious titer, to the Adenovirus Reference Material. These assignments allow the Adenovirus Reference Material to be used as a yardstick for adenovirus vector particle unit and adenovirus vector infectious unit measurements by other methods.
The Adenovirus Reference Material is also undergoing stability testing and purity analyses. A five-year stability study was set up to monitor the reference material when stored frozen at on a more limited basis, when frozen at -80ºC but stored long-term at -20ºC. Stability is being monitored via particle concentration by OD260nm in SDS, particle quality and concentration via Anion Exchange HPLC Assay (4), activity by Infectious Titer Assay (both the ARMWG procedure and a flow cytometry-based institution-specific method also incorporating the NAS calculation), particle size by photon correlation spectroscopy, particle aggregation by absorbance ratio at OD 320nm to OD 260nm, and, for selected time points, a qualitative assessment of micro-aggregation via electron microscopy and assessment of sterility as a correlative for container integrity.
A short-term field use and shipping configuration study is being performed. The field use study focuses on the impact of one, two, or three freeze-thaw cycles, the impact of thaw and subsequent storage at 2-8ºC over 7 days, and the impact of thaw and subsequent storage at room temperature over 7 days. Eight methods will be used to determine stability: the ARMWG procedure for OD260nm in SDS, the ARMWG procedure for infectious titer, a flow cytometrybased infectious titer assay, an Anion-Exchange HPLC assay, assessment of appearance, pH, and assessment of aggregation status via photon correlation spectroscopy and dynamic light scattering. The shipping condition stability study examines the impact on the Reference Material when packaged on dry ice using the ATCC shipping configuration with the package held for two days at 40ºC and then an additional day at 50ºC. Together these studies will provide users the information they need to handle the Reference Material.
A variety of purity analyses will also be performed by participating laboratories. This includes analysis of free hexon levels, analysis of 31K MW protein content (7), analysis of residual 293 The Working Group believes that we have established a model for development of reference materials for viral vectors and other biological materials. The success the Working Group has had in achieving our mission has been due to a clear understanding of our goals, the transparency of the process, and the highly collaborative effort that had input from all arenas in the field. This input came from regulatory authorities, standardization organizations such as USP and NIBSC, academic laboratories, industry/sponsor Quality Assurance, Quality Control, and Manufacturing representatives, contract manufacturing and testing organizations, and suppliers, as well as representation from outside the U.S. Another factor in completing the mission quickly was the fact that nearly every company actively developing adenoviruses as therapeutic products was involved in the Working Group or in submitting proposals to participate. These groups put aside their proprietary stances and cooperated to achieve something of benefit to the entire field.
Compromise was required by participants and achieved because the Working Group continually asking how proposals and decisions would fit with the goals. 
